Q98.0 Insurance Policy Changes

ICD-10 Q98.0 is officially defined as "Klinefelter syndrome karyotype 47, XXY." code Q98.0 is referenced in 5 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Q98.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 19, 2026Medium impact
Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)
Aetna's Clinical Policy Bulletin 0358 considers invasive prenatal diagnosis by chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS, cordocentesis) medically necessary for diagnosing fetal chromosomal abnormalities. Preimplantation genetic testing for monogenic disorders (PGT-M) is medically necessary only when the listed criteria are met, including a known carrier parent for the specific indication, a specific identified mutation, and a procedure that eliminates the need for later invasive prenatal diagnosis. PGT-A, PGT-M for fetal chromosomal abnormalities, PGT-M to determine HLA status for stem cell donation, multigene panels at PGT-M testing, and invasive screening or PGT for a variant of uncertain significance are considered experimental, investigational, or unproven, as are the Igenomix PGT-M, PGT-SR, Smart PGT-A and Smart PGT-A Plus tests, the IriSight Prenatal Analysis, and the Natera Spectrum PGT-M test.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Free Testosterone Testing
Serum free testosterone (CPT 84402) is medically necessary to distinguish a sex hormone-binding globulin (SHBG) abnormality from hypogonadism in obese males with symptoms of hypogonadism when total testosterone is low, to diagnose hyperandrogenism in symptomatic females, and in patients with a medical diagnosis that may increase or decrease SHBG levels. It is not medically necessary to diagnose testosterone deficiency in non-obese males with symptoms of hypogonadism, or when performed for screening of asymptomatic patients. Free testosterone should be performed by equilibrium dialysis, and free testosterone measured by an analog method should never be ordered.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Estrogen Hormone Testing: Estradiol and Estrone
Measurement of estrogen hormones is considered medically necessary to evaluate ovarian function in females with symptoms of hypoestrogenism or hyperestrogenism, to diagnose hyperestrogenism in symptomatic males, to monitor hormone replacement therapy in postmenopausal females, and to monitor antiestrogen therapy. Measurement of estrogen hormones is considered not medically necessary when performed for screening purposes in asymptomatic patients. The covered tests are total estradiol (CPT 82670), fractionated estrogens (CPT 82671), total estrogens (CPT 82672), estrone (CPT 82679), and free estradiol by direct measurement, such as equilibrium dialysis (CPT 82681).
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Testosterone Replacement Therapy
Injectable testosterone cypionate and testosterone enanthate do not require prior authorization, and prior authorization is only required for non-injectable testosterone formulations. For Androgel, Testim, or Testopel requests, testosterone replacement is medically necessary when the individual has a documented diagnosis of a pituitary tumor, Klinefelter's syndrome, Kallmann's syndrome, or bilateral orchiectomy, or a documented diagnosis of hypogonadism with signs and symptoms of low testosterone and two low total testosterone levels from morning samples collected between 8:00 a.m. and 10:00 a.m. on different days. Aveed, Axiron, Azmiro, Fortesta, Natesto, Vogelxo, Xyosted, and oral testosterone products are considered not medically necessary because other formulary options exist.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Testosterone Replacement Therapy
Testosterone replacement therapy may be considered medically necessary when the individual has a documented pituitary tumor, Klinefelter's syndrome, Kallmann's syndrome, or bilateral orchiectomy, or a documented diagnosis of hypogonadism with signs and symptoms of low testosterone and two low total testosterone levels from morning samples collected between 8:00 a.m. and 10:00 a.m. on different days. Injectable testosterone cypionate or injectable testosterone enanthate meets the therapy requirement directly, while Testopel requires documentation of an appropriate trial of both injectable products that did not adequately raise testosterone to within normal limits. Aveed and Azmiro are considered not medically necessary because other formulary options exist, and testosterone replacement is not medically necessary if the only symptom is erectile dysfunction or impotence.

Watch Q98.0

Get one email when a payer policy names Q98.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Q98.0?

There are 5 tracked policy changes affecting code Q98.0, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Q98.0?

Payers that have issued tracked updates for code Q98.0 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Q98.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Q98.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Q98.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)

Free Testosterone Testing

Estrogen Hormone Testing: Estradiol and Estrone

Testosterone Replacement Therapy

State and School Employees' Health Insurance Plan - Testosterone Replacement Therapy

What insurance policy changes affect code Q98.0?

Which payers have updated policy for code Q98.0?

How do I get notified when code Q98.0 policy changes?

Why do payers change policies for code Q98.0?